Illumina stock gains 3.20 percent as S&P 500 exposure expands

Illumina stock closed at USD 255.38 on Nasdaq on September 23, 2026, up 3.20 percent from USD 247.46. The move came as the company entered several S&P 500-related indexes and raised its 2026 outlook, while its share price stood 0.31 percent below the 52-week high of USD 256.17.

Q2 revenue reached USD 1.16 billion

Illumina reported second-quarter 2026 revenue of USD 1.16 billion, a 9.5 percent increase from USD 1.06 billion in the same quarter of 2025, according to ScanX. Non-GAAP diluted EPS rose 10 percent year over year to USD 1.31, while GAAP diluted EPS reached USD 1.35.

The operating mix was important. Sequencing instruments revenue rose 31 percent to USD 125 million, and the company placed more than 95 NovaSeq X systems during the quarter, according to ScanX. Clinical consumables revenue increased 15 percent excluding China, contrasting with a 7 percent decline in research and applied-market sequencing consumables outside China.

Guidance rises as index exposure expands

Illumina lifted its full-year 2026 reported revenue guidance by USD 50 million at the midpoint to USD 4.60 billion to USD 4.64 billion. The company also guided to non-GAAP diluted EPS of USD 5.30 to USD 5.40 and rest-of-world organic revenue growth above 5 percent, according to ScanX.

MarketScreener reported that Illumina was added to the S&P 500 Health Care index, alongside additions to other S&P 500-related benchmarks. That creates a measurable ownership-related backdrop for a stock already trading near its yearly high.

UBS target reaches USD 260

On September 9, 2026, UBS upgraded Illumina from Neutral to Buy and raised its price target from USD 135 to USD 260, as reported by MarketScreener. The new target is 1.82 percent above the September 23 closing price, leaving the rating change and the raised company guidance as the two clearest reference points for the current valuation.

Stock trades near yearly high

Illumina closed at USD 255.38 on Nasdaq on September 23, 2026, with a market capitalization of USD 38.64 billion. Its 52-week range was USD 88 to USD 256.17, placing the stock 0.31 percent below the upper end of that range.